The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
PDE4 inhibitors: current status
Open accessAbstract
Phosphodiesterase4 inhibitors are currently under development for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease. The rationale for the development of this drug class stems from our understanding of the role of PDE4 in suppressing the function of a range of inflammatory and resident cells thought to contribute toward the pathogenesis of these diseases. Similarly, numerous preclinical in vivo studies have shown that PDE4 inhibitors suppress characteristic features of these diseases, namely, cell recruitment, activation of inflammatory cells and physiological changes in lung function in response to a range of insults to the airways. These potentially beneficial actions of PDE4 inhibitors have been successfully translated in phase II and III clinical trials with roflumilast and cilomilast. However, dose limiting side effects of nausea, diarrhoea and headache have tempered the enthusiasm of this drug class for the treatment of these respiratory diseases. A number of strategies are currently being pursued in attempts to improve clinical efficacy and reduce side effects, including delivery via the inhaled route, and/or development of non‐emetic PDE4 inhibitors and mixed PDE inhibitors. British Journal of Pharmacology(2008)155, 308–315; doi:fn1; published online 28 July 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenosine 3‘,5‘-Phosphate in Biological Materials
Butcher, R. W., & Sutherland, E. W. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60316-3 · Cited by 2,077
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
How corticosteroids control inflammation: Quintiles Prize Lecture 2005
Barnes, P. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706736 · Cited by 838
Phosphodiesterase Isozymes: Molecular Targets for Novel Antiasthma Agents
TORPHY, T. J. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9708012 · Cited by 657
Keynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635
Sildenafil, a novel effective oral therapy for male erectile dysfunction
Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J. (1996) · British Journal of Urology · doi:10.1046/j.1464-410x.1996.10220.x · Cited by 564
Histone acetylation and deacetylation: importance in inflammatory lung diseases
Barnes, P. J., Adcock, I. M., & Ito, K. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00117504 · Cited by 564
Lehnart, S. E., Wehrens, X. H. T., Reiken, S., Warrier, S., Belevych, A. E., Harvey, R. D., Richter, W., Jin, S.-L. C., Conti, M., & Marks, A. R. (2005) · Cell · doi:10.1016/j.cell.2005.07.030 · Cited by 517
Epithelium dysfunction in asthma
Holgate, S. T. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.10.025 · Cited by 489
Cited by
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
Burgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjornsson, J. M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 397
Progress in the mechanism and targeted drug therapy for COPD
Wang, C., Zhou, J., Wang, J., Li, S., Fukunaga, A., Yodoi, J., & Tian, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00345-x · Cited by 303
Metadata
- Authors
- Spina, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-10
- Volume
- 155
- Issue
- 3
- Pages
- 308-315
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2101175089
- Cited by
- 340
- References
- 65
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PDE4 inhibitors: current status. https://app.cochat.ai/papers/10.1038/bjp.2008.307
- The paper
- Spina, D. (2008). PDE4 inhibitors: current status. British Journal of Pharmacology. https://doi.org/10.1038/bjp.2008.307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
